Eli Lilly reported significant revenue growth from its weight-loss drugs Mounjaro and Zepbound, achieving $5.2 billion and $3.4 billion in sales respectively. The company holds 57% of the market share for these drugs. Mounjaro has shown cardiovascular benefits, while orforglipron led to an average loss of 27.3 pounds in a clinical trial. Despite these successes, Eli Lilly's stock fell over 14%. In contrast, competitor Novo Nordisk's shares increased despite disappointing earnings, as Eli Lilly's products generate increased competition in the weight-loss drug market.
In the company's second quarter earnings report, Eli Lilly reported that sales of Mounjaro reached nearly $5.2 billion, up 68% from the previous year.
Similarly, Zepbound saw $3.4 billion in sales, up 172% year-over-year, exceeding estimates of $3 billion.
Mounjaro demonstrated its ability to protect cardiovascular health in recent trial results.
Orforglipron helped patients lose an average of 27.3 pounds in a phase three clinical trial.
Collection
[
|
...
]